Variability in total serum IgE over 1 year in severe asthmatics.

Autor: Louis R; 1Service de Pneumologie-Allergologie, CHU Sart Tilman B35, 4000 Liege, Belgium., Pilette C; 2Cliniques Universitaires Saint-Luc, Avenue Hippocrate 10, 1200 Brussels, Belgium., Michel O; 3CHU Brugmann, Place A.Van Gehuchten 4, 1020 Brussels, Belgium., Michils A; 4CUB Hôpital Erasme, Route de Lennik 808, 1070 Brussels, Belgium., Brusselle G; 5UZ Gent, Corneel Heymanslaan 10, 9000 Ghent, Belgium., Poskin A; 6Novartis Pharma, Medialaan 40, 1800 Vilvoorde, Belgium., Van Schoor J; 6Novartis Pharma, Medialaan 40, 1800 Vilvoorde, Belgium., Denhaerynck K; Matrix45, LLC, 6159 West Sunset Road, Tucson, AZ 85743 USA.; 8University of Basel, Basel, Switzerland., Vancayzeele S; 6Novartis Pharma, Medialaan 40, 1800 Vilvoorde, Belgium., Abraham I; Matrix45, LLC, 6159 West Sunset Road, Tucson, AZ 85743 USA., Gurdain S; 6Novartis Pharma, Medialaan 40, 1800 Vilvoorde, Belgium.
Jazyk: angličtina
Zdroj: Allergy, asthma, and clinical immunology : official journal of the Canadian Society of Allergy and Clinical Immunology [Allergy Asthma Clin Immunol] 2019 Mar 29; Vol. 15, pp. 20. Date of Electronic Publication: 2019 Mar 29 (Print Publication: 2019).
DOI: 10.1186/s13223-019-0331-8
Abstrakt: Background: Immunoglobulin E (IgE) is the treatment target of omalizumab, a monoclonal antibody indicated in the treatment of severe allergic asthma. Long-term variability of serum total IgE (sIgE tot ) in asthmatics remains poorly documented.
Methods: In this prospective study, sIgE tot levels were measured over 1 year at 7 time points in 41 severe asthmatics treated with high-dose of inhaled corticosteroids and long-acting β 2 agonists. 33 patients were atopic based on at least one positive RAST to common aeroallergens. Patients were divided into three groups according to their baseline sIgE tot level: low (< 76 IU/mL; n = 10), intermediate (76-700 IU/mL; n = 20) or high (> 700 IU/mL; n = 11). Patients also completed the six-item Juniper Asthma Control Questionnaire (ACQ 6 ). The sIgE tot variability and factors predictive for this variability were studied, as well as ACQ 6 outcomes.
Results: The variation in sIgE tot level was mostly the consequence of between patient-variability, which represented 96%, 71% and 96% of the total variability in the low, intermediate and high sIgE tot subgroups, respectively. The residual within-patient variability was therefore limited. In 10/41 patients, sIgE tot levels increased or decreased, for at least one visit, beyond the predefined range of the subgroups to which they were assigned (< 76 IU/mL; 76-700 IU/mL; > 700 IU/mL). There was a significant but weak correlation between sIgE tot and ACQ 6 score over all time points (r = 0.15, p = 0.02), but sIgE tot failed to associate with severe exacerbation. sIgE tot decreased by 3% with any additional year of age for the whole group (p = 0.01) and increased by 5% per one unit of allergen exposure score in atopic patients (p = 0.002).
Conclusion: In severe asthmatics, limited within-patient variability of sIgE tot levels was observed over 1 year as opposed to marked between-subject variability. sIgE tot decreases with age. Variation in sIgE tot weakly associates with asthma control but not with exacerbation.
Competing Interests: GB, RL, AM, OM and CP are members of an Advisory Board of Novartis Pharma, Belgium. IA and KD work for Matrix45, LLC. By company policy employees are prohibited from owning equity in or perform services independently for sponsor organizations. Matrix45 provides similar services to other biopharmaceutical on a non-exclusivity basis. SG, AP, JVS and SV are employees of Novartis Pharma, Belgium.
Databáze: MEDLINE
Externí odkaz:
Nepřihlášeným uživatelům se plný text nezobrazuje